The FASTER trial studies whether a combination of anti-CD38 antibody and an BCMA-directed bispecific T-cell engager can outperform autologous stem cell transplantation and anti-CD38 antibody plus lenalidomide maintenance in patients with newly diagnosed multiple myeloma.
